BACKGROUND: Recent studies suggest that insulinoma-associated protein 1 (INSM1) is a sensitive and specific marker of neuroendocrine neoplasms. The aims of this study were to determine whether INSM1 can be reliably used in cytology (Cellient) cell blocks, to ascertain whether staining correlates with paired surgical pathology specimens, and to compare its sensitivity and specificity with those of synaptophysin (SYN), chromogranin (CHR), and CD56 for neuroendocrine lung tumors. METHODS: Seventy-four primary lung neoplasms diagnosed on cytology were stained with INSM1, SYN, CHR, and CD56: 41 small cell lung carcinomas (SCLCs), 1 large cell neuroendocrine carcinoma (LCNEC), 10 carcinoid tumors, 11 adenocarcinomas, 9 squamous cell carcinomas, 1 mesothelioma and 1 poorly differentiated non-small cell lung carcinoma, not otherwise specified. In 20 cases, a paired surgical pathology specimen was also stained with INSM1. RESULTS: INSM1 was positive in 48 of 52 primary lung neuroendocrine neoplasms (92%), including 38 of 41 SCLCs (93%), the only LCNEC (100%), and 9 of 10 carcinoid tumors (90%), and it was negative in all 22 non-neuroendocrine primary lung tumors. For SCLC, the sensitivity of INSM1 (93%) was lower than the sensitivity of CD56 (100%), equal to the sensitivity of SYN (93%), and higher than the sensitivity of CHR (35%). For carcinoid tumors, the sensitivity of INSM1 (90%) was lower than the sensitivity of all other markers (100% each). The specificity of INSM1 for neuroendocrine neoplasms as a group was 100%. 
INTRODUCTION
Insulinoma-associated protein 1 (INSM1), a 510-amino acid protein with 5 zinc finger motifs at the carboxyl terminus, is a developmentally regulated transcription factor involved in the development of neuroendocrine differentiation. 1, 2 Its complementary DNA, known as insulinoma-associated 1 (IA-1), was isolated in 1992 from a human insulinoma subtraction library. 3 Subsequently, Northern blot analysis showed that the corresponding messenger RNA was expressed in neuroendocrine neoplasms such as small cell lung carcinomas (SCLCs), pulmonary carcinoid tumors, pheochromocytomas, and medullary thyroid carcinomas but not in non-neuroendocrine tumors. 4 Recent evidence suggests that INSM1 expression may be associated with chemosensitivity in SCLC cell lines. 5 In the realm of diagnostic pathology, interest in INSM1 has burgeoned with recent publications in the surgical pathology literature demonstrating its high sensitivity and specificity for neuroendocrine neoplasms of various organs. [6] [7] [8] [9] [10] One of these investigations, which focused on INSM1 expression in lung neoplasms, led the authors to suggest that INSM1 may supplant traditional neuroendocrine markers for the diagnosis of neuroendocrine neoplasms of the lung. 10 To our knowledge, the utility of INSM1 immunohistochemistry in cytologic specimens has not been reported. Specifically, at the time of this writing (December 2017), there were no published studies of INSM1 staining in cell blocks prepared from cytopathology samples from the respiratory tract. The aims of this study were 1) to determine whether INSM1 can be reliably used in cytopathology cell block material obtained from lung tumors, 2) to ascertain whether INSM1 staining in cytology samples correlates with corresponding surgical pathology specimens, and 3) to compare the sensitivity and specificity of INSM1 for neuroendocrine tumors of the lung with those of synaptophysin (SYN), chromogranin (CHR), and CD56.
MATERIALS AND METHODS
The Cleveland Clinic institutional review board for the protection of human subjects approved this study (institutional review board number 17-985).
Case Selection
We selected cases by conducting a retrospective search of our laboratory information system (CoPathPlus; Cerner Corporation, Kansas City, Missouri) to identify primary lung neoplasms diagnosed on cytology from May 2015 to September 2017, and cases were included in the study if a cell block was available for immunohistochemistry. The cases were enriched for neuroendocrine neoplasms and for tumors in which a corresponding surgical pathology specimen (biopsy or resection) was available.
Cell blocks from 74 primary lung neoplasms (52 neuroendocrine neoplasms and 22 non-neuroendocrine neoplasms) diagnosed on cytology, including 41 SCLCs, 1 large cell neuroendocrine carcinoma (LCNEC), 10 carcinoid tumors, 11 adenocarcinomas, 9 squamous cell carcinomas, 1 mesothelioma, and 1 poorly differentiated nonsmall cell lung carcinoma, not otherwise specified (NSCLC, NOS), were retrieved, and the cell block slides were reviewed. The cytology specimen types for these cases were as follows: 69 transbronchial fine-needle aspiration biopsies, 4 computed tomography-guided lung fine-needle aspiration specimens, and 1 fluid cytology specimen. These specimens were obtained from 42 women and 32 men, who ranged in age from 29 to 87 years (mean, 64 years). The original diagnosis was confirmed in all cases with standard morphologic criteria. For 31 of the 41 SCLCs, immunohistochemistry was used at the time of the original diagnosis, whereas 10 were diagnosed by morphology alone. All of the 31 cases for which immunohistochemistry had been used for diagnosis were positive for at least 1 neuroendocrine marker. The LCNEC was diagnosed as "highgrade neuroendocrine carcinoma consistent with LCNEC" on cytology and as "non-small cell carcinoma consistent with LCNEC" on the corresponding biopsy. Eight of the 10 carcinoid tumors were resected; 7 were classified as typical carcinoid tumors, and 1 was classified as an atypical carcinoid tumor. The mesothelioma was diagnosed as "atypical mesothelial proliferation" on cytology and as "malignant mesothelioma, epithelioid type" on the corresponding pleural biopsy (and subsequent pleurectomy).
Cytology Specimen Processing
Body fluids were collected fresh, whereas fine-needle aspiration specimens were collected in ThinPrep CytoLyt solution. All cases were processed on a ThinPrep 2000 automated slide preparation unit (Hologic, Inc, Bedford, Massachusetts). Cellient cell blocks were prepared with the Cellient automated cell block system (Hologic) according to the manufacturer's instructions.
Immunohistochemistry
Cellient cell block sections from all cases were stained with antibodies to INSM1 (A-8), SYN, CHR, and CD56. In 20 cases, a paired surgical pathology specimen ( Three traditional neuroendocrine markers were used: CD56 (rabbit monoclonal anti-CD56 antibody, clone MRQ-42; Cell Marque Corp, Rocklin, California), SYN (mouse monoclonal anti-SYN antibody, clone Snp88; BioGenex, Fremont, California), and CHR (mouse monoclonal anti-chromogranin A antibody, clone DAK-A3; Agilent, Santa Clara, California). All 3 antibodies used the Ventana OptiView DAB Detection Kit with the BenchMark Ultra automated stainer. CD56 and SYN arrived prediluted, whereas chromogranin A was diluted 1:100 with the Ventana antibody diluent. Tonsillar tissue was used as the positive control for CD56, and pancreatic tissue was the positive control for all other markers.
Interpretation of Immunohistochemical Findings
For INSM1, any nuclear staining was interpreted as positive. 10 For SYN and CHR, any granular cytoplasmic staining was considered positive. Any cytoplasmic or membrane staining was considered positive for CD56. Staining intensity was characterized as weak, moderate, or strong. For all markers, less than 10% staining was classified as focal.
RESULTS
The results are summarized in Table 1 . INSM1 was positive in 48 of 52 primary neuroendocrine neoplasms of the lung (92%), including 38 of 41 SCLCs (93%), 9 of 10 carcinoid tumors (90%), and the only LCNEC (100%). All 22 non-neuroendocrine lung neoplasms, including 11 adenocarcinomas, 9 squamous cell carcinomas, 1 NSCLC, NOS, and 1 mesothelioma, were INSM1-negative. For SCLC, the sensitivity of INSM1 (93%) was less than the sensitivity of CD56 (100%), equivalent to the sensitivity of SYN (93%), and greater than the sensitivity of CHR (35%). For carcinoid tumors, the sensitivity of INSM1 (90%) was less than the sensitivity of each of the other markers (100% each). The single case of LCNEC was positive for INSM1 as well as the other 3 markers. The sensitivity of INSM1 for neuroendocrine lung neoplasms as a group (92%) was less than the sensitivity of CD56 (100%) but was comparable to the sensitivity of SYN (94%) and considerably higher than the sensitivity of CHR (49%). In SCLCs that stained positively for INSM1, staining was moderate to strong in most cases (31 of 38 [82%]) and weak in the remainder (7 of 38 [18%]). The distribution of staining was diffuse in the majority of cases (29 of 38 [76%]; Fig. 1 ). However, 9 cases showed only focal staining (<10% of tumor cells). Table 2 shows various permutations of neuroendocrine marker staining encountered in cases of SCLC in Cellient cell blocks in this study. The most common pattern was positive staining for INSM1, SYN, and CD56 and an absence of staining for CHR (19 cases). The next most common permutation was positive staining for all 4 markers (15 cases). The 3 INSM1-negative SCLCs were all positive for CD56 and SYN but were negative for CHR. There were no SCLCs for which INSM1 was the sole positive neuroendocrine marker. In addition, there was not a single case of SCLC in which all 4 neuroendocrine markers used in this study were negative. In the single case of LCNEC, INSM1 staining was weak and very focal (1% of tumor cells). Four of 9 INSM1-positive carcinoid tumors showed weak staining, whereas 5 showed moderate to strong staining. Only 1 carcinoid tumor was negative for INSM1; this case showed strong and diffuse staining for SYN, CHR, and CD56. The subsequent resection showed an atypical carcinoid tumor. Figure 2 shows an example of INSM1 staining in a carcinoid tumor. All 22 non-neuroendocrine tumors were negative for INSM1 (Fig. 3) .
SYN was positive in 37 of 40 SCLCs (93%), the only LCNEC (100%), 10 of 10 carcinoid tumors (100%), and 1 of 10 adenocarcinomas (10%) and was negative in 9 squamous cell carcinomas, 1 NSCLC, NOS, and 1 mesothelioma. The single SYN-positive adenocarcinoma was strongly and diffusely positive for SYN but was negative for INSM1, CHR, and CD56. On the cytologic specimen, 
Abbreviations: CHR, chromogranin; INSM1, insulinoma-associated protein 1; LCNEC, large cell neuroendocrine carcinoma; NSCLC, NOS, non-small cell lung carcinoma, not otherwise specified; SCLC, small cell lung carcinoma; SYN, synaptophysin.
the tumor had the typical appearance of an adenocarcinoma, and it consisted of clusters of malignant cells with prominent nucleoli and vacuolated cytoplasm; morphologic features suggestive of neuroendocrine differentiation were not present. Subsequent resection showed a micropapillary-predominant adenocarcinoma. CHR was positive in 14 of 40 SCLCs (35%), 10 of 10 carcinoid tumors (100%), and the only LCNEC (100%). It was negative in all non-neuroendocrine tumors tested (10 adenocarcinomas, 9 squamous cell carcinomas, 1 NSCLC, NOS, and 1 mesothelioma). CD56 was positive in 40 of 40 SCLCs (100%), the only LCNEC (100%), 9 of 9 carcinoid tumors (100%), and 1 of 9 squamous cell carcinomas (11%; weak, focal); it was negative in all cases of adenocarcinoma (0 of 10), NSCLC, NOS (0 of 1), and mesothelioma (0 of 1). Table 3 shows the sensitivity, specificity, positive predictive value, and negative predictive value of all 4 markers for primary pulmonary neuroendocrine tumors. The sensitivity of INSM1 for primary pulmonary neuroendocrine neoplasms as a group (92%) was less than the sensitivity of CD56 (100%) and SYN (94%) but was higher than the sensitivity of CHR (49%). The specificity of INSM1 for primary pulmonary neuroendocrine neoplasms (100%) was similar to the specificity of CHR (100%) and was higher than the specificity of SYN (95%) and CD56 (95%).
INSM1 staining in cytology samples was concordant with INSM1 staining in surgical pathology material in all 20 cases with a paired surgical pathology specimen. INSM1 was positive in the Cellient cell block from a cytology sample as well as the surgical pathology specimen for 4 SCLCs and 1 carcinoid tumor (Figs. 4 and 5) and was negative in both specimen types for 9 adenocarcinomas, 4 squamous cell carcinomas, 1 NSCLC, NOS, and 1 mesothelioma. However, the intensity of INSM1 staining was less in Cellient cell blocks than surgical pathology specimens in 3 of 5 cases, and the percentage of INSM1- (Table 4) .
DISCUSSION
The diagnosis of primary neuroendocrine neoplasms of the lung in cytology specimens can be straightforward when the clinical setting and the morphologic findings are classic. As stated in the 2015 World Health Organization classification of lung tumors, the diagnosis in such cases can be made on the basis of standard histologic or cytologic stains without ancillary immunohistochemical testing. 11 However, immunohistochemistry can be helpful when the clinical setting is atypical or when morphologic findings are unusual. In the surgical pathology literature, immunohistochemistry has been shown to improve diagnostic reproducibility for the diagnosis of SCLC. 12 The traditional neuroendocrine markers SYN, CHR, and CD56 are highly sensitive markers of carcinoid tumors and are helpful in many cases of SCLC, but each marker has its limitations. For example, CHR, which is highly specific for neuroendocrine differentiation, lacks sensitivity, whereas CD56, a highly sensitive neuroendocrine marker, can stain non-neuroendocrine tumors, and this limits its specificity. [13] [14] [15] [16] An immunohistochemical marker that could combine high sensitivity with high specificity would thus be valuable, especially for the diagnosis of SCLC.
The main aim of our study was to provide a proof of concept that INSM1 can be reliably used in cytopathology cell block material obtained from lung tumors. Because there are no prior reports describing INSM1 staining in cytologic specimens from the respiratory tract, our central finding-INSM1 stains a high proportion of 
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April 2018 neuroendocrine tumors of the lung in cytopathology cell block material-is novel. The proportion of INSM1-positive neuroendocrine lung tumors in our study is similar to that reported in the surgical pathology literature. The sensitivity of INSM1 for small cell carcinomas in our study was 92% (38 of 41 cases), which is comparable to the sensitivity of 94.9% reported by Rooper et al 10 reported that nearly one-half of antibodies that they initially validated consistently exhibited false-negative staining on Cellient cell blocks when they used immunohistochemical protocols optimized for formalin-fixed, paraffinembedded tissues. In fact, validation failed for 3 antibodies (Ber-EP4, D2-40, and PAX-8) even after they had attempted modifications in immunohistochemical conditions. On the basis of their findings, Sauter et al proposed criteria for the validation of immunohistochemical protocols for antibodies on Cellient cell blocks. The criteria (TN 1 FN) . require concordant staining in expected positive cells in at least 5 of 5 cases and concordant staining in expected negative cells in at least 5 of 5 cases. 18 Our findings fulfill these validation criteria because concordant staining in expected positive cells was seen in 5 of 5 cases and concordant staining in expected negative cells was observed in 15 of 15 cases. Although separate validation of antibodies in alcohol-fixed cytopathologic material is needed, the use of a liquid-based cytopathology platform is advantageous because the preparation of Cellient cell blocks is fully automated and reliable. This technique is also faster and less labor-intensive than the preparation of formalin-fixed, paraffin-embedded cell blocks; this could improve the workflow in cytopathology laboratories with a large volume of cases. Furthermore, ThinPrep slides can easily be prepared from the same sample vial, and they offer a thin monolayer of cells for ease of interpretation. Finally, molecular testing can be performed either on the cell pellet or on the supernatant of any leftover sample.
Our final goal was to compare the sensitivity and specificity of INSM1 for neuroendocrine tumors of the lung with those of the traditional neuroendocrine markers SYN, CHR, and CD56. In our series, INSM1 was more sensitive for neuroendocrine lung neoplasms as a group than CHR, was nearly as sensitive as SYN, and was less sensitive than CD56. Its specificity for neuroendocrine tumors was identical to the specificity of CHR and higher than the specificity of SYN and CD56. When it was analyzed by tumor type, INSM1 was slightly inferior to traditional markers for the diagnosis of carcinoid tumors of the lung in terms of both sensitivity and intensity of expression. For SCLC, INSM1 was slightly superior to SYN in that the sensitivities of the 2 markers for SCLC were identical but the specificity of INSM1 was slightly higher. INSM1 was also superior to CHR because its sensitivity was significantly higher, whereas the specificities of the 2 markers were identical. The value of INSM1 versus CD56 was more difficult to analyze. Whether the higher sensitivity of CD56 for SCLC is offset by its lower specificity as a neuroendocrine marker is a valid and open question, which should be addressed in future studies. When the 3 traditional markers were analyzed as a group against INSM1 as a standalone marker (Table 3) , the sensitivity of INSM1 was lower (92% vs 100%), but its specificity for pulmonary neuroendocrine neoplasms was higher (100% vs 90%).
Although this study is one of the largest analyses of SCLC with INSM1 to date, it includes relatively small numbers of other tumors that might enter the differential diagnosis of small cell carcinoma. We also did not focus on-or enrich our cases for-diagnostically difficult tumors, where the role of INSM1 would be interesting to study. Additional data from other investigators will be required to determine whether INSM1 is superior to traditional neuroendocrine markers. More data are also required to address the question of whether the replacement of traditional neuroendocrine markers by INSM1 is justified, required, or feasible. Because traditional neuroendocrine markers show excellent performance in the diagnosis of carcinoid tumors, it is unlikely that INSM1 will replace them for this purpose. It is in the diagnosis of SCLC that INSM1 is most promising, especially because nuclear markers are easy to interpret, complement cytoplasmic or membrane stains, and are useful in the presence of marked crush artifacts or in cases with extensive necrosis, in which the interpretation of traditional neuroendocrine markers may be difficult.
In conclusion, INSM1 shows promise as a robust nuclear marker of neuroendocrine neoplasms on cytopathology (Cellient) cell block material obtained from lung tumors. We have shown that INSM1 staining in cytology cell block samples correlates well with corresponding surgical pathology specimens, although our study contained a limited number of cases with cytopathologichistopathologic correlation. For primary neuroendocrine neoplasms of the lung, INSM1 combines high sensitivity (slightly less than the sensitivity of CD56) with high specificity (similar to the specificity of CHR).
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